Janssen unveils positive pivotal data for first potential two-drug HIV regimen

14 February 2017

US healthcare giant Johnson & Johnson’s (NYSE: JNJ) subsidiary Janssen announced that HIV maintenance therapy with a two-drug regimen of rilpivirine and dolutegravir is as effective as current standard three- or four-drug antiretroviral regimens over 48 weeks.

The positive results from the pivotal Phase III SWORD 1&2 trials were presented during a press meeting at the annual Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle; a detailed press release is below.

Dolutegravir (trade name Tivicay) was developed by ViiV Healthcare, which is majority-owned by GlaxoSmithKline (LSE: GSK), while rilpivirine (trade name Edurant) is a Janssen product.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK